Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

KIORA PHARMACEUTICALS INC Director's Dealing 2016

Mar 31, 2016

35256_dirs_2016-03-31_2abfeca8-9cdd-403b-91ff-4ce92c92ce18.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2016-03-29

Reporting Person: Chaoui Mounia (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2016-03-29 Stock Option (right to buy) $3.06 A 2416 Acquired 2026-03-29 Common Stock (2416) Direct

Footnotes

F1: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on March 29, 2017, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.